pharma companies in
India and out-license
Stempeucel® drug for key
indications addressing
unmet medical needs
and generate significant
revenue. Apart from that
we also aim to work on
globalizing Stempeucel®
drug in key markets like
US and Europe. For that
get necessary regulatory
approvals from FDA &
EMA. Also, it is important
for us to generate
significant revenue
through Stempeucare®
range of cosmetics
products in India besides
complete Stempeutron™
device development
and commercialization
in India. Our long term
vision is to make the
Stempeutics a significant
player in the area of stem
cells in Asia.
KEY MILESTONES FOR STEMPEUTICS SINCE ITS
INCEPTION IN 2006
Jan, 2006: Formation of company at Bangalore. R&D of Stempeucel®
product
May, 2008: Establishment of manufacturing facility at Manipal
March, 2009: Phase 1 clinical trial approval granted by DCGI for the
treatment of CLI
October, 2011: Phase 2 clinical trial approval granted by DCGI for the
treatment of CLI
December, 2014: Applied for Manufacturing & Marketing Approval in
India
February, 2015: US Patent Office granting process patent for
Stempeucel® product
March, 2015: European Medicinal Agency granting ATMP status for
Stempeucel® product
May, 2015: European Medicinal Agency granting ODD status for
Stempeucel® product
February, 2016: Limited approval granted by DCGI
March, 2017: Manufacturing & Marketing approval granted by DCGI
in Form 46
BIOVOICENEWS.COM
45